The Immunology Core (Core E) provides immunologic assays, reagents and expertise to support innovative aasic, clinical and translational HIV/AIDS research by Penn CFAR members, with the overall goal of improving our understanding of the pathogenesis and immunopathogenesis of HIV infection and AIDS; introducing new approaches for investigating immune function;developing novel immunotherapy or gene therapy strategies for viral control or immune reconstitution;and basic discovery and translational development of vaccine strategies. To support this mission, the Immunology Core offers a wide range of services to benefit all CFAR members performing HIV related immunoldgical research: (1) """"""""Self-service"""""""" support including validated reagents and materials that are widely used among the member labs, including purified primary human blood cell subsets and Qdot labeled antibodies for polychromatic flow cytometry;(2) """"""""Full service"""""""" support that performs standard immunological assays using AACTG and PACTG approved protocols on samples provided by CFAR members;flow cytometric-based assays including phenotyping and intracellular cytokine measurements;and a BSL3 sorting facility enabling """"""""live"""""""" sorts of infectious material, and;(3) Training, education and support in the use of reagents, assays, or techniques, as well as consultation and collaboration for immunology-based projects. In the coming cycle, we will provide the CFAR community with access and expertise to use an exciting new human immune system mouse with which to study HIV-1 pathogenesis and vaccines in an in vivo model.
HIV-1 is a virus that attacks the immune system. Having access to key immunological reagents, assays and expertise will allow Penn CFAR investigators to make more rapid progress in understanding the underlying cause of HIV-1 pathogenesis and to evaluate new therapies or vaccines to fight or prevent HIV-1 infection.
|Ojikutu, Bisola O; Bogart, Laura M; Higgins-Biddle, Molly et al. (2018) Facilitators and Barriers to Pre-Exposure Prophylaxis (PrEP) Use Among Black Individuals in the United States: Results from the National Survey on HIV in the Black Community (NSHBC). AIDS Behav 22:3576-3587|
|Martei, Yehoda M; Pace, Lydia E; Brock, Jane E et al. (2018) Breast Cancer in Low- and Middle-Income Countries: Why We Need Pathology Capability to Solve This Challenge. Clin Lab Med 38:161-173|
|Wood, Sarah; Ratcliffe, Sarah; Gowda, Charitha et al. (2018) Impact of insurance coverage on HIV transmission potential among antiretroviral therapy-treated youth living with HIV. AIDS 32:895-902|
|Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912|
|Genn, Leah; Chapman, Jennifer; Okatch, Harriet et al. (2018) Pharmacy Refill Data are Poor Predictors of Virologic Treatment Outcomes in Adolescents with HIV in Botswana. AIDS Behav :|
|Shin, S S; Modongo, C; Zetola, N M et al. (2018) High rates of exposure to tuberculosis patients among HIV-infected health care workers in Botswana. Int J Tuberc Lung Dis 22:366-370|
|Abbas, Arwa A; Young, Jacque C; Clarke, Erik L et al. (2018) Bidirectional transfer of Anelloviridae lineages between graft and host during lung transplantation. Am J Transplant :|
|Goldberg, Drew W; Tenforde, Mark W; Mitchell, Hannah K et al. (2018) Neurological Sequelae of Adult Meningitis in Africa: A Systematic Literature Review. Open Forum Infect Dis 5:ofx246|
|Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :|
|Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187|
Showing the most recent 10 out of 775 publications